TLDR Patients with cutaneous lupus are most concerned about self-consciousness, physical symptoms, and disease progression.
This study aimed to identify concerns unique to patients with cutaneous lupus erythematosus (CLE) through semistructured, qualitative interviews with 16 patients. The interviews revealed six main themes: Fear of Disease Progression, Unwanted Attention, Self-Consciousness, Physical Signs/Symptoms, Emotional Symptoms, and Functional Decline. The most commonly reported concerns were Self-Consciousness (81.3%), Physical Symptoms (75%), and Fear of Disease Progression (68.8%). Frequently mentioned physical symptoms included erythema, itch, dyspigmentation, scar, and alopecia. Younger patients were more likely to report emotional symptoms than older patients. These findings highlight the importance of addressing these specific concerns in clinical evaluations and quality-of-life assessments for CLE patients.
23 citations,
November 2013 in “Lupus” Therapeutic intervention improved the quality of life for Japanese lupus patients with skin issues.
158 citations,
March 2011 in “Journal of the American Academy of Dermatology” Patients with cutaneous lupus erythematosus have a severely impaired quality of life, especially emotionally.
149 citations,
July 2002 in “Dermatologic clinics” Patients with certain skin symptoms and high ANA titers should be monitored for potential systemic lupus.
52 citations,
March 2007 in “Dermatologic Therapy” The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.
2 citations,
January 2006 in “Technical report” The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.
158 citations,
March 2011 in “Journal of the American Academy of Dermatology” Patients with cutaneous lupus erythematosus have a severely impaired quality of life, especially emotionally.
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
59 citations,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
